Prevencio, a leader in AI-powered cardiovascular diagnostics, received new patents in the United Kingdom and Hong Kong for its HART CADhs® test, expanding its global portfolio to six patents. The test uses multiple protein biomarkers and machine learning to noninvasively diagnose obstructive coronary artery disease.
Prevencio Receives FDA Breakthrough Device Designation for HART CADhs, Its Artificial Intelligence-driven Blood Test for Obstructive Coronary Artery Disease
Share: